Podcast appearances and mentions of von willebrand disease

Editor's note: The Virginia Mercury is not using the last names of the women in this article to protect their privacy and safety. The accounts of all three women have been verified with medical records and by a medical professional with knowledge of their experiences. Nisa knew her third pregnancy was a non-starter. She didn't know that she would fear death for 18 days while trying to get an abortion. “I felt like I had a ticking time bomb inside of me,” she said. This is because Nisa has Von Willebrand Disease, a genetic blood disorder that prevents clotting. It...Article LinkSupport the show

This episode covers von Willebrand disease.Written notes can be found at https://zerotofinals.com/medicine/haematology/vonwillebranddisease/ or in the haematology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.

This week in our hematological consultation series, we continue our discussion on von Willebrand disease (vWD), this time focusing on the type 2 subtypes and we also discuss management.In case you missed it, we recommend checking out episode 069 for Part I of this vWD series, covering taking a bleeding history and about Type 1 and Type 3 disease.Content: - What testing do we send for suspected vWD (refresher)- What to do if type 2 vWD is suspected?- What are the different subtypes of Type 2 vWD?- What is "platelet-type vWD"? - What is the approach to perioperative management? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

We resume our hematological consultation series with an overview of von Willebrand disease, the most common inherited bleeding disorder. In this episode, we talk about the initial steps we should take to evaluate suspected von Willebrand disease (vWD) and how to differentiate the various subtypes. We will focus on vWD type 1 and 3! Be sure to tune in next week as we discuss vWD type 2 and management.Content: - Taking a bleeding history - What is von Willebrand factor? - What tests should we order for diagnosis? - What are the different types of vWD?- What is the DDAVP challenge? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Normal 30-40 seconds Indications Identifying congenital deficiencies in clotting Monitoring heparin therapeutic levels (PT for warfarin) Monitoring effects of: Liver Disease Protein Deficiency Fat malabsorption on clotting Description Activated Partial Thromboplastin Time (aPTT) is a test that measures the amount of time it takes for a fibrin clot to form after reagents have been added to the specimen. It is useful in diagnosing clotting disorders. In conjunction with PT it can be used to differentiate the specific factor that may be missing. What would cause increased (Prolonged) levels? Vitamin K Deficiency Disseminated Intravascular Coagulation (DIC) Hemodialysis Patients Afibrinogenemia Polycythemia Liver disease Von Willebrand Disease. What would cause decreased levels? N/A

COR2ED Medical Education: Haematologists Prof. Ana Boban and Dr Jonathan Roberts discuss how the type of von Willebrand disease (VWD) impacts the treatment. In this podcast, aimed at healthcare professionals outside of haematology, the experts summarise the key treatment options for VWD and discuss how they make treatment decisions on a daily basis, including treatments they tend to avoid in certain types of the disease. They also consider management in some specific clinical scenarios, including a spontaneous bleed, surgery, and heavy menstrual bleeding. Prof. Ana Boban is Head of the Haemophilia Centre, University Hospital Centre Zagreb, Croatia, and Dr Jonathan Roberts is Associate Medical Director, Associate Research Director, Bleeding and Clotting Disorders Institute, Peoria, IL, USA.

In this episode, we review the high-yield topic of Von Willebrand Disease from the Heme section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

This week's episode will be focusing on a bleeding disorder, Von Willebrand disease (VWD). We will go over all the important details on the diagnosis, types of VWD (& ways to remember them!) as well as treatment options.

Does your head spin when you look at a von Willebrand panel? In this episode, Dr. Angela Weyand teaches us about the most typical presentations of VWD, how to interpret those pesky antigen and activity levels, and how DDAVP works for bleeds.

Von Willebrand disease (VWD) is a hereditary quantitative deficiency or functional abnormality of von Willebrand factor (VWF), which causes platelet dysfunction. Bleeding tendency is usually mild in the most common types, but it can be severe and present with factor VIII deficiency as well as platelet dysfunction in the rarer subtypes. It is diagnosed based on testing von willebrand factor antigen levels which is low in most subtypes, VWF activity which is low in most subtypes and VWF multimer distribution which is abnormal in a small number of the subtypes.  Treatment depends on the degree of bleeding. Mild mucosal bleeding can often be managed with tranexamic acid alone to help stabilise the clots that are present. Desmopressin might be used in more significant bleeding or perioperatively. Occasionally von willebrand factor concentrates might need to be given. Follow us on Instagram @yourekiddingrightdoctors Our email is yourekiddingrightpod@gmail.com Make sure you hit SUBSCRIBE/FOLLOW so you don't miss any episodes and RATE to help other people find us! (This isn't individual medical advice, please use your own clinical judgement and local guidelines when caring for your patients)

Today, Nick and Fei are joined by Dr. David Abel to discuss Von Willebrand Disease. We review its importance both in the Gyn and the Ob patient. Dr. Abel is an assistant professor in the Division of Perinatology at Oregon Health and Science University.  Twitter: @creogsovercoff1 Instagram: @creogsovercoffee Facebook: www.facebook.com/creogsovercoffee Website: www.creogsovercoffee.com Patreon: www.patreon.com/creogsovercoffee You can find the OBG Project at: www.obgproject.com

Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.

Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.

Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.

Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.

Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.

Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.

Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.

Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.

In this episode, we review the high-yield topic of Von Willebrand Disease from the Hematology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

Hemophilia A & B, Von Willebrand Disease, Factor V Leiden, Protein C & S Deficiency review for your Pance, Panre and EOR's. DB link (save 10% off by clicking the link!) https://bit.ly/37cP8YP ►Paypal Donation Link: https://bit.ly/3dxmTql (Thank you!) --- Support this podcast: https://anchor.fm/scott--shapiro/support

Join Yvonne Brandenburg, RVT, VTS SAIM and Jordan Porter RVT, LVT, VTS SAIM as we talk about: von Willebrand disease and how it can affect more than just Dobermans! Question of the Week: What are some breeds of dogs or cats you've seen vWB disease in? Thanks so much for tuning in. Join us again next week for another episode!  Want to earn some RACE approved CE credits for listening to the podcast? You can earn between 0.5-1.0  hour of RACE approved CE credit for each RACE approved podcast episode you listen to.    Join the Internal Medicine For Vet Techs Membership to earn and keep track of your continuing education hours as you get your learn on!   Join now! http://internalmedicineforvettechsmembership.com/   Get Access to the Membership Site for your RACE approved CE certificates Sign up at https://internalmedicineforvettechsmembership.com  Get Access to the Technician Treasure Trove  Sign up at https://imfpp.org/treasuretrove    Thanks for listening!  – Yvonne and Jordan

Earlier this year, clinical practice guidelines for the diagnosis and management of von Willebrand disease (VWD) were published in Blood Advances. The guidelines (https://bit.ly/2OIfKLE) are a collaborative effort from the American Society of Hematology, the International Society on Thrombosis and Haemostasis, the National Hemophilia Foundation, and the World Federation of Hemophilia. Guideline author Paula James, MD, of Queens University, Kingston, Ont., reviews some of the recommendations in these guidelines with host David H. Henry, MD, in this episode. Case discussion A patient presents with the complaint of heavy menstrual bleeding, which could indicate a bleeding disorder such as VWD. How does one diagnose or rule out VWD? Tests to order include CBC, prothrombin time (PT), and partial thromboplastin time (PTT). Results of CBC, PT, and PTT could be normal, which would necessitate special testing to specifically look at factor VIII and von Willebrand factor (VWF). A patient’s family history may be helpful, as most types of VWD are autosomal dominant, though two subtypes are recessive. Diagnostic evaluation of VWD VWF is the chaperone protein for factor VIII in the intrinsic pathway, which is measured by the PTT. In more severe forms of VWD, the PTT is prolonged because of factor VIII. VWF is measured separately because it is not reflected in the PT or PTT. The recommendation is to measure VWF antigen and employ a functional assay to see how well VWF binds platelets. The recommendation in the new guidelines is to use the GPIbM assay rather than the ristocetin cofactor assay. Many labs in the United States are still using the ristocetin cofactor assay. However, in Canada, Europe, and other parts of the world, many labs have moved to a newer assay that is automated. It has a much lower coefficient of variation and fewer issues with measurement of VWF in Black populations, which is a major issue with the cofactor assay. Types of VWD Type 1 VWD is characterized by a decreased amount of VWF. Type 1 patients have low VWF antigen and low platelet-dependent VWF function to a similar degree, with low or normal factor VIII. Type 2 VWD is characterized by aberrant VWF. The functional assay is a lot lower than VWF antigen. The platelet-dependent function to VWF antigen ratio cutoff is 0.7. Further testing is warranted to determine subtypes (2A, 2B, 2N, or 2M), including VWF multimers. Genetic testing can be helpful to further delineate subtypes. Type 3 VWD is characterized by the absence of VWF. The patient will have a VWF antigen level of 0, platelet-dependent VWF function of 0, and a reduced factor VIII level (usually less than 10%). Pregnant patients with VWD There is a protective adaptation in pregnancy, in which factors normalize in the third trimester, which works to prevent hemorrhage at delivery. This protective effect is because of the hormonal changes of pregnancy, and it is seen in patients with milder forms of VWD. WVF levels peak within 8-24 hours after delivery and then slowly return to baseline. There is a risk of delayed postpartum hemorrhage once VWF levels return to baseline, which tends to happen 7-14 days postpartum. Procedural planning: Desmopressin challenge test Desmopressin causes the release of VWF from the Weibel-Palade bodies of the endothelium, and it can be used as prophylaxis or treatment of bleeding in type 1 VWD. The desmopressin challenge test is used to check how the patient responds to desmopressin when well, to predict the patient’s response after an anticipated procedure. The test involves measuring VWF levels before desmopressin is given and at 1 hour, 2 hours, and 4 hours after desmopressin administration. The idea is to measure the magnitude of increase in VWF levels and observe how sustained that increase is to predict the patient’s response to desmopressin after future procedures. There is a subset of patients with type 1 VWD who have increased clearance of VWF that causes their decreased VWF levels. They may not have a sustained plateau in the VWF level after desmopressin, which emphasizes why testing as far as 4 hours after desmopressin administration is important. The dose of desmopressin given in this test is typically 0.3-0.4 mcg/kg. Recommendations for preprocedure prophylaxis for type 1 VWD Minor procedures (e.g., wisdom tooth extraction) The patient should receive an antifibrinolytic agent, such as tranexamic acid or aminocaproic acid, 2 hours before the procedure, followed by desmopressin 30-60 minutes prior to the procedure. After the procedure, the patient should continue to receive the antifibrinolytic agent for 3-4 days. Major procedures/surgeries (e.g., gallbladder removal) The guidelines do not recommend desmopressin for major procedures because patients need to be fluid-restricted for approximately 24 hours after administration because of the risk of hyponatremia. Desmopressin is a synthetic analog of vasopressin, which results in the accumulation of free water similarly to vasopressin. The guidelines do recommend giving VWF-containing concentrate to increase VWF and factor VIII to greater than 50% from baseline for at least 3 days. VWF concentrates can be given every 12 hours or as continuous intravenous infusions. Tranexamic acid should be given as an adjuvant both prior to the procedure and in the days following. Cryoprecipitate is not recommended because it can’t be virally inactivated.  Preprocedure prophylaxis in type 2 or 3 VWD Desmopressin does not work for most patients with type 2 or 3 VWD. So even for minor procedures, these patients will need to receive VWF concentrate coupled with antifibrinolytics. Show notes written by Sheila DeYoung, DO, a resident at Pennsylvania Hospital, Philadelphia. Disclosures Dr. Henry has no relevant disclosures. Dr. James disclosed relationships with Baxter/Baxalta/Shire, CSL Behring, Bayer, and Octapharma. *  *  * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd

This weekly addition to the PAINE Podcast is a quick review and history of medical eponyms

Patrick and Amy discuss the long-awaited Von Willebrand Disease (vWD) guidelines published in the medical journal, Blood; provide an exciting update on a recent “Believe 19” guest, and speak to Camille Proctor, founder of The Color Of Autism Foundation.   Notes: PRESENTING SPONSOR: Takeda - bit.ly/TakedaBDsite   vWD Clinical Guidelines: http://bit.ly/vWDguidelines FLOW podcast: http://bit.ly/FLOWBSM PHILLY Famous podcast: http://bit.ly/PhillyFamousPodcast COLOR of Autism Foundation: http://bit.ly/ColorOfAutism   SUBSCRIBE to BloodStream on Apple Podcasts - bit.ly/BSPAP LIKE BloodStream on Facebook - bit.ly/BSFB20 WATCH BloodStream on YouTube - bit.ly/BSPYT20   #hemophilia #vonwillebranddisease #vwd #autism #podcast

In this episode we take a deep dive into a rare bleeding disorder- Von Willebrand Disease! We discuss the importance of VW factor, the different types of VWD, common symptoms, pertinent investigations and an approach to management. Check out our associated infographic at www.theinternatwork.com.  

This episode covers von willebrand disease!

This episode covers von willebrand disease!

Podcast summary of articles from the May 2020 edition of the Journal of Emergency Medicine from the American Academy of Emergency Medicine.  Topics include shotgun injuries, N95 mask reuse, presentation times of MI, infection in patients with falls, pain control in pediatric patients, and board review on Hemophilia and Von Willebrand Disease.  Guest speaker is Dr. Ryan Yavorksy.

A sip of Von-Willebrand disease --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/snapmd/message

Dr Will Lester explains how best to approach the diagnosis and how management differs depending on the subtype

In this episode I cover haemophilia A and haemophilia B.If you want to follow along with written notes on haemophilia go to https://zerotofinals.com/medicine/haematology/haemophilia/ or the haematology section in the Zero to Finals medicine book.This episode covers the definitions, types, tests, causes and treatments of haemophilia. The audio in the episode was expertly edited by Harry Watchman.

In this episode I cover von Willebrand disease.If you want to follow along with written notes on von Willebrand disease go to https://zerotofinals.com/medicine/haematology/vonwillebranddisease/ or the haematology section in the Zero to Finals medicine book.This episode covers the definitions, types, tests, causes and treatments of von Willebrand disease. The audio in the episode was expertly edited by Harry Watchman.

This podcast will provide an approach to, and management of pediatric von Willebrand disease. It was developed by Chen Jin, a medical student at the University of Alberta, with the help of Dr. Mia Lang, a pediatrician at the University of Alberta.

On this episode of "World of Promise," Dr. Andra James of Duke University School of Medicine discusses Von Willebrand Disease, how it affects women and girls, and the promise of biotechnology to improve the lives of people with bleeding disorders. This episode also features Mary Ann Massolio, who is living with Von Willebrand Disease, and insights from Debbie Bensen-Kennedy of CSL Behring. 

In this episode, qualified Naturopath Ashleigh Mythen talks with Jenna Lovell - a freelance writer and editor. Who at the age of just 16 was diagnosed with a rare inherited bleeding disorder called Von Willebrand Disease or VWD for short. She is an advocate of women and girls in her illness community and has done a lot of exploring and experimenting with lifestyle factors such as diet, excercise and Chinese Medicine to support and manage her symptoms. Jenna has been blogging about her bleeding disorder, health and life for over 5 years at mymissingfactor.com Some of the things you'll discover in this week's episode are: + Jenna Lovell's inspiration to begin sharing and blogging her experiences + Jenna's personal insight and journey from chronically ill to chronically thriving + What is Von Willebrand Disease (VWD) and what it's like to live on a day to day basis with a chronic disorder + How Jenna juggle's her business and her life around having a chronic disease + The impact and importance of excercise on your physical and mental health + How blending nutrition, lifestyle changes and Chinese Medicine changed her life + The importance of blending different therapies to find what works for you + Advice for people beginning the journey of chronically ill to be able to chronically thrive + Road blocks to health and how to bypass fear and that inner critic to get the results you want + Why having health goals helps create health outcomes + 3 things Jenna does every day to say healthy + AND SO MUCH MORE!!   RESOURCES + Chinese medicine doctor Dr Nat Kringoudis + Jenna's barre & reformer Pilates classes she attends in Hobart as well as in Melbourne + Bianca Potenta interview episode 004 is HERE   CONNECT WITH JENNA LOVELL + Website: mymissingfactor.com/ + Facebook: www.facebook.com/mymissingfactor/ + Instagram: www.instagram.com/mymissingfactor/   REVIEW Your written reviews and feedback inspire me to improve each episode. Plus they help spread the it can't be that friggin hard message far and wide. If you love the podcast and the information shared then please leave a review and rating over at iTunes or stitcher. I would also really love to hear about your own health journey, what your struggling with and what you'd love to hear covered in upcoming episodes please leave me a comment below or reach out to me at Ashleigh@itcantbethatfrigginhard.com   WEEKLY NEWSLETTER For weekly health tips, tricks and other goodies straight to your inbox, sign up to my weekly newsletter   [mc4wp_form id="9"]  

This month on BloodStream, we review major takeaways from World Federation of Hemophilia’s 2018 World Congress, Dakota Rosenfelt shares his journey of life with hemophilia, and we speak with Lisa Thibeault, the nurse coordinator from the Southeastern Ontario Regional Inherited Bleeding Disorders Program in Ontario, Canada, about the progress made in the treatment of women with bleeding disorders. All that and more on Episode 25 of The BloodStream Podcast! Exclusive Sponsor: Shire World Federation of Hemophilia 2018 World Congress World Congress Daily Recaps FDA Clears way for gene therapy BioMarin presents data on BMN 270 Bayer presents insights on HemACTIVE study Novo Nordisk presents data on Rebinyn and presents study data on NovoEight CSL Behring Supports patient advocacy groups through LEAD Program Octapharma presents data on SubQ-8 and presents data on Nuwiq UniQure presents data their AAV5 gene therapy program Bioverativ (a Sanofi company) presents preliminary data for BIVV001 Shire presents data on rVWF in the treatment of people with VWD National Hemophilia Foundation’s Dawn Rotellini elected to WFH’s Board of Directors. Genentech/Roche received Priority Review from the FDA for Hemlibra in Hem A patients without inhibitors. coreHEM publishes Core Outcome Set for Hemophilia Clinical Trials Spark and Pfizer present data on SPK-9001 and the modified process New study looks at Von Willebrand Disease, Von Willebrand Factor, and Aging   Latest Ask The Expert Podcast: Episode 15 featuring Shari Luckey.  Latest Powering Through Podcast: Episode 17 featuring Vanessa Flora, Jason Flora, and Heather Stephenson Share Segment: Dakota Rosenfelt - A Prescription for Success Interview Segment: Lisa Thibeault, RN - Let’s Talk Period, from Queen’s University + partners   BloodFeed: https://www.bloodfeed.com Connect with BloodStream: Email mailbag@bloodstreammedia.com Find all of our bleeding disorders podcasts on BloodStreamMedia.com BloodStream Facebook Page BloodStream Twitter Account Subscribe to BloodStream: iTunes: http://bit.ly/bloodstreamitunes Stitcher: http://bit.ly/bloodstreamstitcher LibSyn: http://bit.ly/bloodstreamlibsyn SoundCloud: http://bit.ly/bloodstreamSC TuneIn: http://bit.ly/bloodstreamtunein Google Play: http://bit.ly/bloodstreamPlay Spotify: http://spoti.fi/2nNPhui

Von Willebrand Disease

This month on The BloodStream Podcast, we discuss how one executive director in China has creatively given hope, dignity and income to her patients, we take you through how to stay fit and healthy while travelling, and we introduce a brand new game here on the BSpod. Plus, Hannah Lutz shares her story of life with Type 3 Von Willebrand Disease and Michael Hargett- the hemophiliac who lost 280 pounds and became the first person with hemophilia to undergo a heart transplant- joins us as today’s interview guest to discuss his remarkable journey. All that and more on Episode 21 of The BloodStream Podcast!   Exclusive Sponsor: Shire Remembering Barry Haarde: Powering Through HFA 2016 Like Segment: How to Fit in Exercise While You Travel   Share Segment: Hannah Lutz - Type Three Girl    Comment Segment: How Paper and Scissors Gave Back Dignity to Hemophilia Patients   Interview Segment: Michael Hargett’s NewHeart4Mike.com website   Community News in 60 Seconds: Registration for NHF’s Washington Days Registration for NHF’s Bleeding Disorders Conference Patient Access Network Foundation Opens Hemophilia Patient Assistance Fund Hemophilia Puts Damper on Patient’s Sex Life and Health Status, Study Reports My Life, Our Future to be Featured in CDC Public Health Webinar NORD Launches 7,000 Mile Rare Movement Rebinyn Now Available for the Treatment of Hemophilia B Sanofi, Facing Threat From Generics, Moves to Buy Hemophilia Drug Makers (Bioverativ) Europe’s CHMP Recommends Approval of Hemlibra to Treat Hemophilia A (with Inhibitors) Shire Granted European Union Marketing Authorization for Adynovi   Parting Shots: #EAHAD2018 on Twitter   Other Links of Interest Project CALLS from Hemophilia Federation of America HTCtour.org- Stop The Bleeding’s Guided Tour of a Hemophilia Treatment Center BloodStreamMedia.com Powering Through Podcast Ask The Expert Podcast   BloodFeed: https://www.bloodfeed.com Connect with BloodStream: Email mailbag@bloodstreammedia.com Find all of our bleeding disorders podcasts on BloodStreamMedia.com BloodStream Facebook Page BloodStream Twitter Account Subscribe to BloodStream: iTunes: http://bit.ly/bloodstreamitunes Stitcher: http://bit.ly/bloodstreamstitcher LibSyn: http://bit.ly/bloodstreamlibsyn SoundCloud: http://bit.ly/bloodstreamSC TuneIn: http://bit.ly/bloodstreamtunein Google Play: http://bit.ly/bloodstreamPlay Spotify: http://spoti.fi/2nNPhui

This month on The BloodStream Podcast, Shire and Roche are locked up in a legal dispute related to Hemlibra, what does this mean and will it impact patients’ ability to receive Hemlibra? We discuss in today’s Comment Segment. A New York Times article examines why the United States spends so much more money on healthcare than any other country in a story presented by Natalie in our Like Segment, and entrepreneur and hemo dad Mark Kenny shares his compelling story and perspective during our Share Segment. Plus Natalie and I sit down with hemo mom (and Patrick’s mom!) Susan Lynch to get her perspective of being introduced to hemophilia in the mid-1980’s and how she navigated being a single parent of two kids with hemophilia during the advent of recombinant products and prophylaxis. All that and more on this Episode 20 of The BloodStream Podcast! Exclusive Sponsor: Shire Like Segment:  Why the US spends so much more money on other nation’s than Healthcare. Share Segment: Mark Kenny: Entrepreneur and Hemo Dad  Comment Segment: Shire and Roche locked in legal dispute over Hemlibra. Links: From Biopharma Dive, “Shire looks to stall Hemlibra impact with court injunction” From Reuters, “Roche, Shire court fight escalates over haemophilia drug” From Shire, “Shire Files Preliminary Injunction Against Roche to Protect Its Intellectual Property”   Parting Shots: Syria allows some patients to leave besieged area Von Willebrand Disease in Dogs: Symptoms, Causes, & Treatments Woman awarded £9m damages for care of son who 'should not have been born'   Other Links of Interest World Federation of Hemophilia’s Government Support in Armenia Chris Bombardier’s Adventures of a Hemophiliac Facebook Page Powering Through Podcast Ask The Expert Podcast   BloodFeed: https://www.bloodfeed.com Connect with BloodStream: Email mailbag@bloodstreammedia.com Find all of our bleeding disorders podcasts on BloodStreamMedia.com BloodStream Facebook Page BloodStream Twitter Account Subscribe to BloodStream: iTunes: http://bit.ly/bloodstreamitunes Stitcher: http://bit.ly/bloodstreamstitcher LibSyn: http://bit.ly/bloodstreamlibsyn SoundCloud: http://bit.ly/bloodstreamSC TuneIn: http://bit.ly/bloodstreamtunein Google Play: http://bit.ly/bloodstreamPlay

The BloodLine Podcast presents: von Willebrand Disease (vWD), Part 3 - The Community & The Future Patient communities have started organizing and increasing educational opportunities for people living with vWD, thanks in large part to rising awareness of the disorder around the country and the world. This episode features some profound, challenging and inspiring stories of how the vWD community is connecting, growing and changing. You'll meet patients and clinicians and hear their stories, and their perspectives on the future of vWD treatment, management, and community-building. Stream or download the episode today by visiting www.BloodLinePod.com! BloodLine is a BloodStream Media podcast series featuring deep dives into the stories that matter most. This three-episode series focuses on von Willebrand Disease, and features stories of people affected by vWD alongside interviews with clinical experts.  The series is sponsored exclusively by Shire and is intended to reduce the marginalization of people w/ vWD, increase clinical and organizational focus on vWD, and to give a voice to the diverse experiences of patients and families affected by vWD.  For more information on living with von Willebrand Disease please visit BeyondTheBleed.com

The BloodLine Podcast presents: von Willebrand Disease (vWD), Part 2 - Life with vWD vWD affects patients and their families in numerous ways. This episode, the second of three in our long-form podcast series on vWD, features powerful patient stories on the various experiences of living with the vWD, including combating stigma and the reductive outlooks on vWD. The stories run the gamut from heart breaking to uplifting and inspiring, and they'll certainly be familiar to anyone who lives with vWD or loves someone with vWD.  Stream or download the episode today by visiting www.BloodLinePod.com! BloodLine is a BloodStream Media podcast series featuring deep dives into the stories that matter most. This three-episode series focuses on von Willebrand Disease, and features stories of people affected by vWD alongside interviews with clinical experts.  The series is sponsored exclusively by Shire and is intended to reduce the marginalization of people w/ vWD, increase clinical and organizational focus on vWD, and to give a voice to the diverse experiences of patients and families affected by vWD. For more information on living with von Willebrand Disease please visit BeyondTheBleed.com 

   The BloodStream Podcast - Episode 11 - Program Notes   Listen to Episode 11 by clicking the play button on the audio player above, or follow any of these links to listen and subscribe on your podcast player of choice (recommended):   iTunes: http://bit.ly/bloodstreamitunes Stitcher: http://bit.ly/bloodstreamstitcher LibSyn: http://bit.ly/bloodstreamlibsyn SoundCloud: http://bit.ly/bloodstreamSC TuneIn: http://bit.ly/bloodstreamtunein Google Play: http://bit.ly/bloodstreamPlay   Description: In this episode, Patrick and Natalie celebrate World Hemophilia Day with two special segments: an interview recap with Patrick of Believe Limited's recent trip to Nepal for production on Bombardier Blood and a mashup of soundbites and interview clips from Believe's production on the World Federation of Hemophilia's Treatment for All web series. All that, plus a few special announcements and a brief recap of Hemophilia Federation of America's Annual Symposium on Episode 11 of The BloodStream Podcast!   The BloodStream Podcast is sponsored exclusively by Shire. Learn more about Shire in the bleeding disorders community: Link.   Program Notes: Learn more about World Hemophilia Day from the World Federation of Hemophilia (WFH): Link Check out Stop The Bleeding!’s Season 7 launch w/ their a World Hemophilia Day special episode: Link. Listen to BloodStream Media’s new Von Willebrand Disease podcast series from BloodLine: Link. Check out Hemophilia Federation of America’s website for more on the 2017 and 2018 Symposiums: Link.   Special Segments Learn more about Chris Bombardier’s historic climb of Mount Everest as well as Bombardier Blood, the documentary film being produced about it: Link. Watch all 10 episodes of WFH’s Treatment for All web series and learn more about their Humanitarian Aid Program: Link. Contact BloodStream Media: Got an idea for a future segment, or a question for Ask The Expert? Email us: mailbag@bloodstreammedia.com.   BloodStream Media on Social: BloodStream Facebook Page BloodStream Twitter Account BloodStream Host Patrick James Lynch on Twitter and Instagram.   Subscribe to The BloodStream Podcast: iTunes: http://bit.ly/bloodstreamitunes Stitcher: http://bit.ly/bloodstreamstitcher LibSyn: http://bit.ly/bloodstreamlibsyn SoundCloud: http://bit.ly/bloodstreamSC TuneIn: http://bit.ly/bloodstreamtunein Google Play: http://bit.ly/bloodstreamPlay  

The BloodLine Podcast presents: von Willebrand Disease (vWD), Part 1 - Diagnosis & Management What is von Willebrand Disease (vWD), how is it managed, and what is the common perception of this condition? In this podcast episode, the first of three in a new long-form audio experience on vWD, you'll hear patients and clinicians from around the world share personal stories of diagnoses, learning about vWD, and learning to manage the condition.  Stream or download the episode today by visiting www.BloodLinePod.com! BloodLine is a BloodStream Media podcast series featuring deep dives into the stories that matter most. This three-episode series focuses on von Willebrand Disease, and features stories of people affected by vWD alongside interviews with clinical experts.  The series is sponsored exclusively by Shire and is intended to reduce the marginalization of people w/ vWD, increase clinical and organizational focus on vWD, and to give a voice to the diverse experiences of patients and families affected by vWD.  For more information on living with von Willebrand Disease please visit www.BeyondTheBleed.com